Latest & greatest articles for levothyroxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levothyroxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levothyroxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levothyroxine

1. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. (PubMed)

Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. Thyroid peroxidase antibodies are associated with an increased risk of miscarriage and preterm birth, even when thyroid function is normal. Small trials indicate that the use of levothyroxine could reduce the incidence of such adverse outcomes.We conducted a double-blind, placebo-controlled trial to investigate whether levothyroxine treatment would increase live-birth rates among euthyroid women who had thyroid (...) peroxidase antibodies and a history of miscarriage or infertility. A total of 19,585 women from 49 hospitals in the United Kingdom underwent testing for thyroid peroxidase antibodies and thyroid function. We randomly assigned 952 women to receive either 50 μg once daily of levothyroxine (476 women) or placebo (476 women) before conception through the end of pregnancy. The primary outcome was live birth after at least 34 weeks of gestation.The follow-up rate for the primary outcome was 98.7% (940 of 952

2019 NEJM

2. Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels

Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels - GOV.UK GOV.UK uses cookies to make the site simpler. Search Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels Monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month (...) after starting and ending ritonavir treatment. Published 11 October 2018 From: Therapeutic area: , , Contents Advice for healthcare professionals: reduced thyroxine levels have been reported in patients concomitantly taking ritonavir-containing products and levothyroxine monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month after the start and end of ritonavir treatment report suspected adverse drug reactions resulting from interactions

2018 MHRA Drug Safety Update

3. Levothyroxine

Levothyroxine Top results for levothyroxine - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for levothyroxine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

4. Levothyroxine: problems caused by a change in formulation were foreseeable

Levothyroxine: problems caused by a change in formulation were foreseeable Prescrire IN ENGLISH - Spotlight ''Levothyroxine: problems caused by a change in formulation were foreseeable'', 1 February 2018 {1} {1} {1} | | > > > Levothyroxine: problems caused by a change in formulation were foreseeable Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight (...) Levothyroxine: problems caused by a change in formulation were foreseeable The specificities of levothyroxine mean that it was foreseeable that a change in formulation would require a careful rebalancing of the treatment for some patients. Following a change in the formulation of Levothyrox° tablets in France in March 2017, thousands of patients reported suffering from various disorders which they believed were related to the new brand. This change was requested by the French medicines agency in 2012

2018 Prescrire

5. General medicine: Low-dose levothyroxine did not improve symptoms in asymptomatic older people with subclinical hypothyroidism

General medicine: Low-dose levothyroxine did not improve symptoms in asymptomatic older people with subclinical hypothyroidism Low-dose levothyroxine did not improve symptoms in asymptomatic older people with subclinical hypothyroidism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose levothyroxine did not improve symptoms in asymptomatic older people with subclinical hypothyroidism Article Text Commentary General medicine Low

Full Text available with Trip Pro

2018 Evidence-Based Medicine (Requires free registration)

6. Effect of Levothyroxine on Miscarriage Among Women With Normal Thyroid Function and Thyroid Autoimmunity Undergoing In Vitro Fertilization and Embryo Transfer: A Randomized Clinical Trial. (PubMed)

Effect of Levothyroxine on Miscarriage Among Women With Normal Thyroid Function and Thyroid Autoimmunity Undergoing In Vitro Fertilization and Embryo Transfer: A Randomized Clinical Trial. Presence of thyroid autoantibodies in women with normal thyroid function is associated with increased risk of miscarriage. Whether levothyroxine treatment improves pregnancy outcomes among women undergoing in vitro fertilization and embryo transfer (IVF-ET) is unknown.To determine the effect of levothyroxine (...) on miscarriage among women undergoing IVF-ET who had normal thyroid function and tested positive for thyroid autoantibodies.An open-label, randomized clinical trial involving 600 women who tested positive for the antithyroperoxidase antibody and were being treated for infertility at Peking University Third Hospital from September 2012 to March 2017.The intervention group (n = 300) received either a 25-μg/d or 50-μg/d dose of levothyroxine at study initiation that was titrated according to the level

Full Text available with Trip Pro

2017 JAMA

7. Immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine

Immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine Prescrire IN ENGLISH - Spotlight ''In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine'', 1 November 2017 {1} {1} {1} | | > > > In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight In the November issue of Prescrire International: immunoallergic reactions with nifuroxazide; adverse effects of levothyroxine FREE DOWNLOAD This month's sample page from the Adverse Effects section demonstrates the wide range of information available every month in Prescrire International. Full text available for free download. Nifuroxazide: serious immunoallergic reactions Nifuroxazide is used

2017 Prescrire

8. Levothyrox (levothyroxine): a change in formulation results in thousands of reports of adverse effects

Levothyrox (levothyroxine): a change in formulation results in thousands of reports of adverse effects Prescrire IN ENGLISH - Spotlight ''Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects'', 18 September 2017 {1} {1} {1} | | > > > Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Lévothyrox° (levothyroxine): a change in formulation results in thousands of reports of adverse effects In France, the lactose in Lévothyrox° (levothyroxine) tablets was replaced by mannitol and citric acid was added as a preservative. According to France's national medicines agency (ANSM), two pharmacokinetics studies demonstrated that the old and the new tablets were bioequivalent. A pharmacovigilance

2017 Prescrire

9. Adding carbimazole to levothyroxine increases triiodothyronine and improves outcome in patients with primary hypothyroidism: a preliminary study from Egypt (PubMed)

Adding carbimazole to levothyroxine increases triiodothyronine and improves outcome in patients with primary hypothyroidism: a preliminary study from Egypt Many hypothyroid patients are not tolerant and not satisfied with levothyroxine (LT4). Older studies used large doses of both carbimazole and LT4 for Hashimoto's thyroiditis (HT), because Graves' disease (GD) and HT were considered as very closely related syndromes produced by thyroid autoimmunity.The aim of the study was to determine

Full Text available with Trip Pro

2017 Electronic physician

10. Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Questions for GPs

Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Questions for GPs The BTA is aware that some health authorities are advising GPs to switch patients on Liothyronine (L-T3) to Levothyroxine (L-T4). Whilst we appreciate the commercial imperative to cut prescription costs, like you, our first concern is that in all cases the clinical needs of the patient should come before financial considerations. This frequently asked questions (FAQS) sheet has been produced for GPs who (...) of avoiding under-replacement or over- replacement. The final L-T4 requirement is likely to be around 1.6mcg/kg. Any information about previous L-T4 dosage that achieved a normal serum TSH will be a Switching your patient from Liothyronine (L-T3) to Levothyroxine (L-T4)? Answering GP’s frequently asked questions useful guide. Gradual reduction of L-T3 starting at the same time as introducing or increasing L-T4 may be a preferable alternative. Careful monitoring of the patient by an endocrinologist during

2017 British Thyroid Association

11. Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Information for Endocrinologists

Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Information for Endocrinologists DECEMBER 2016 BRITISH THYROID ASSOCIATION EXECUTIVE COMMITTEE INFORMATION FOR MEMBERS ON PRESCRIBING LIOTHYRONINE (L-T3) The BTA Executive Committee have been made aware of recent difficulties encountered by patients in obtaining Liothyronine (L-T3). In some instances, patients who have long been established on L-T3 have had their treatment abruptly withdrawn and some clinicians have received requests (...) from local health authorities to switch patients from L-T3 to levothyroxine (L-T4). We are concerned that these actions are driven by cost considerations rather than clinical need and that the BTA position statement on the management of hypothyroidism is being inappropriately cited to support this requests. The BTA does not support the sudden withdrawal of L-T3 therapy and this practice does not in any way reflect our position statement. In this document we highlight current problems with L-T3

2017 British Thyroid Association

12. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. (PubMed)

Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. To compare the effects of a unique fixed combination levothyroxine/liothyronine (LT4/LT3) therapy in patients with primary hypothyroidism.This is a randomized, double-blind, crossover study. Adults with primary hypothyroidism (n = 32, age 42.6 ± 13.3, 30 females) on stable doses of LT4 for ≥ 6 months (125 or 150 μg/day) were randomized to continue LT4 treatment (G1) or to start LT4/LT3

Full Text available with Trip Pro

2016 Archives of endocrinology and metabolism

13. A Systematic Review of Clinical Practice Guidelines' Recommendations on Levothyroxine Therapy Alone versus Combination Therapy (LT4 plus LT3) for Hypothyroidism. (PubMed)

A Systematic Review of Clinical Practice Guidelines' Recommendations on Levothyroxine Therapy Alone versus Combination Therapy (LT4 plus LT3) for Hypothyroidism. Patients with hypothyroidism are increasingly enquiring about the benefit of using combination therapy of levothyroxine (LT4) and liothyronine (LT3) as a potential treatment for hypothyroidism. Combination therapy, however, remains controversial. The purpose of this study was to systematically review available hypothyroidism treatment

2015 Clinical and investigative medicine. Médecine clinique et experimentale

14. Levothyroxine or minimally invasive therapies for benign thyroid nodules. (PubMed)

Levothyroxine or minimally invasive therapies for benign thyroid nodules. Thyroid nodules (TN) are common in the adult population. Some physicians use suppressive levothyroxine (LT4) therapy to achieve a reduction in the number and volume of TN. In addition, minimally invasive treatments, such as percutaneous ethanol injection (PEI) sclerotherapy, laser photocoagulation (LP), and microwave (MW), radiofrequency (RF) and high-intensity focused ultrasound (HIFU) ablation, have been proposed

Full Text available with Trip Pro

2014 Cochrane

15. Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation

Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. Published 11 (...) December 2014 From: Therapeutic area: This article has been superseded. Please see updated information on the , October 2016. Article date: March 2012 Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. The CHM review examined sporadic reports of potential reduced efficacy when switching to Teva levothyroxine from other levothyroxine products and evidence of manufacturing

2012 MHRA Drug Safety Update

16. Levothyroxine dose and risk of fractures in older adults: nested case-control study. (PubMed)

Levothyroxine dose and risk of fractures in older adults: nested case-control study. To quantify the effect of levothyroxine dose on risk of fractures in older adults.Nested case-control study.Population based health databases, Ontario, Canada.Adults aged 70 or more prescribed levothyroxine between 1 April 2002 and 31 March 2007 and followed for fractures until 31 March 2008. Cases were cohort members admitted to hospital for any fracture, matched with up to five controls from within the cohort (...) who had not yet had a fracture.Primary outcome was fracture (wrist or forearm, shoulder or upper arm, thoracic spine, lumbar spine and pelvis, hip or femur, or lower leg or ankle) in relation to levothyroxine use (current, recent past, remote). Risk among current users was compared between those prescribed high, medium, and low cumulative levothyroxine doses in the year before fracture.Of 213,511 prevalent levothyroxine users identified, 22,236 (10.4%) experienced a fracture over a mean 3.8 years

Full Text available with Trip Pro

2011 BMJ

17. Levothyroxine Sodium for Injection

Levothyroxine Sodium for Injection Drug Approval Package: Levothyroxine Sodium NDA #202231 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Levothyroxine Sodium for Injection, 100 mcg, 200 mcg, and 500 mcg vials Company: APP Pharmaceuticals, LLC Application No.: 202231 Approval Date: 06/24/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

18. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. (PubMed)

Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. Thyroidal production of triiodothyronine (T3) is absent in athyreotic patients, leading to the suggestion that T3 deficiency may be unavoidable during levothyroxine (LT4) therapy. However, trials evaluating therapy with combined LT4 and T3 have failed to demonstrate any consistent advantage of combination therapy.To determine whether T3 levels in patients treated with LT4 therapy were truly lower than in the same

Full Text available with Trip Pro

2008 JAMA

19. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. (PubMed)

Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. Hypothyroidism during pregnancy has been associated with impaired cognitive development and increased fetal mortality. During pregnancy, maternal thyroid hormone requirements increase. Although it is known that women with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothyroidism occurs in many. In this prospective study we attempted (...) to identify precisely the timing and amount of levothyroxine adjustment required during pregnancy.Women with hypothyroidism who were planning pregnancy were observed prospectively before and throughout their pregnancies. Thyroid function, human chorionic gonadotropin, and estradiol were measured before conception, approximately every two weeks during the first trimester, and monthly thereafter. The dose of levothyroxine was increased to maintain the thyrotropin concentration at preconception values

2004 NEJM

20. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. (PubMed)

Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Standard therapy for patients with primary hypothyroidism is replacement with synthetic thyroxine, which undergoes peripheral conversion to triiodothyronine, the active form of thyroid hormone. Within the lay population and in some medical communities, there is a perception that adding synthetic triiodothyronine, or liothyronine, to levothyroxine improves (...) the symptoms of hypothyroidism despite insufficient evidence to support this practice.To evaluate the benefits of treating primary hypothyroidism with levothyroxine plus liothyronine combination therapy vs levothyroxine monotherapy.Randomized, double-blind, placebo-controlled trial conducted from May 2000 to February 2002 at a military treatment facility that serves active duty and retired military personnel and their family members. The trial included a total of 46 patients aged 24 to 65 years

Full Text available with Trip Pro

2003 JAMA